Cart
sales@molnova.com
CEP dipeptide 1
CAS No. 816432-15-2
CEP dipeptide 1( —— )
Catalog No. M30089 CAS No. 816432-15-2
CEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 311 | Get Quote |
|
| 10MG | 535 | Get Quote |
|
| 50MG | 1596 | Get Quote |
|
| 100MG | 2211 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCEP dipeptide 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).
-
DescriptionCEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number816432-15-2
-
Formula Weight381.42
-
Molecular FormulaC18H27N3O6
-
Purity>98% (HPLC)
-
SolubilityH2O : 10 mg/mL (26.22 mM; Need ultrasonic)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Lu L, et al. Synthesis and structural characterization of carboxyethylpyrrole-modified proteins: mediators of age-related macular degeneration. Bioorg Med Chem. 2009 Nov 1;17(21):7548-61.
molnova catalog
related products
-
RORγ inverse agonist...
RORγ inverse agonist 1 has anti-inflammatory activity and can be used to treat rheumatism and psoriasis.
-
(1S,2S)-threo-Honoki...
(1S,2S)-threo-Honokitriol is a natural product of Magnolia, Magnoliaceae. (1S,2S)-threo-Honokitriol can be used as a reference standard.
-
OVA Peptide 257-264
This is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.
